troglitazone has been researched along with Hyperinsulinism in 39 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Hyperinsulinism: A syndrome with excessively high INSULIN levels in the BLOOD. It may cause HYPOGLYCEMIA. Etiology of hyperinsulinism varies, including hypersecretion of a beta cell tumor (INSULINOMA); autoantibodies against insulin (INSULIN ANTIBODIES); defective insulin receptor (INSULIN RESISTANCE); or overuse of exogenous insulin or HYPOGLYCEMIC AGENTS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine whether amelioration of insulin resistance in polycystic ovary syndrome (PCOS) with the insulin sensitizer troglitazone (TGZ) decreases circulating adrenal androgens (AAs), as reflected by DHEAS levels." | 9.10 | Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome. ( Azziz, R; Ehrmann, DA; Fereshetian, AG; Ghazzi, MN; Legro, RS; O'Keefe, M, 2003) |
| "Troglitazone decreases insulin resistance and hyperglycemia in patients with non-insulin-dependent diabetes mellitus (NIDDM), but its effects on subjects without diabetes are not known." | 9.07 | Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. ( Beerdsen, P; Joyce, M; Ludvik, B; Nolan, JJ; Olefsky, J, 1994) |
| "The aim of this study was to investigate the effects of troglitazone (TRO)--a new insulin-sensitizing agent--on some metabolic parameters in an experimental model of hypertriglyceridemia and insulin resistance, hereditary hypertriglyceridemic rats, and to compare its effects with those of vitamin E, an antioxidant agent." | 7.71 | A comparison of the effects of troglitazone and vitamin E on the fatty acid composition of serum phospholipids in an experimental model of insulin resistance. ( Chvojková, S; Divisová, J; Kazdová, L, 2001) |
| "Troglitazone is a new orally active hypoglycemic agent that has been shown to ameliorate insulin resistance and hyperinsulinemia in both diabetic animal models and non-insulin-dependent diabetes mellitus (NIDDM) subjects." | 7.69 | Metabolic effects of troglitazone on fat-induced insulin resistance in the rat. ( Gao, KM; Khoursheed, M; Lee, MK; Miles, PD; Moossa, AR; Olefsky, JM, 1995) |
| "Troglitazone, a newly developed oral antidiabetic agent, improves hyperglycemia, and has been reported to improve insulin resistance and to decrease hepatic glucose production in diabetic animals." | 7.69 | Effect of troglitazone, a new oral antidiabetic agent, on fructose-induced insulin resistance. ( Higa, S; Ishikawa, K; Mimura, G; Murakami, K; Takasu, N; Yagi, N, 1995) |
| "Insulin resistance is associated with a decreased vasodilator response to insulin." | 6.69 | Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone. ( Lutterman, JA; Ong, MK; Smits, P; Tack, CJ, 1998) |
| "Troglitazone treatment completely prevented the TNF-alpha-induced decline in submaximal GDR (133 +/- 16 vs." | 5.30 | TNF-alpha-induced insulin resistance in vivo and its prevention by troglitazone. ( Cohen, A; Higo, K; Miles, PD; Olefsky, JM; Rafaat, K; Romeo, OM, 1997) |
| "To determine whether amelioration of insulin resistance in polycystic ovary syndrome (PCOS) with the insulin sensitizer troglitazone (TGZ) decreases circulating adrenal androgens (AAs), as reflected by DHEAS levels." | 5.10 | Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome. ( Azziz, R; Ehrmann, DA; Fereshetian, AG; Ghazzi, MN; Legro, RS; O'Keefe, M, 2003) |
| "Troglitazone decreases insulin resistance and hyperglycemia in patients with non-insulin-dependent diabetes mellitus (NIDDM), but its effects on subjects without diabetes are not known." | 5.07 | Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. ( Beerdsen, P; Joyce, M; Ludvik, B; Nolan, JJ; Olefsky, J, 1994) |
| "Troglitazone, a newly introduced insulin sensitizer, has been implicated in prevention and treatment of atherosclerotic cardiovascular disease especially associated with type 2 diabetes mellitus and insulin resistance." | 4.80 | [Cardiovascular effects of the thiazolidinedione troglitazone]. ( Kuzuya, H; Nakano, T; Yamada, K, 2000) |
| "The aim of this study was to investigate the effects of troglitazone (TRO)--a new insulin-sensitizing agent--on some metabolic parameters in an experimental model of hypertriglyceridemia and insulin resistance, hereditary hypertriglyceridemic rats, and to compare its effects with those of vitamin E, an antioxidant agent." | 3.71 | A comparison of the effects of troglitazone and vitamin E on the fatty acid composition of serum phospholipids in an experimental model of insulin resistance. ( Chvojková, S; Divisová, J; Kazdová, L, 2001) |
| " We tested the hypothesis that troglitazone, which improves insulin sensitivity and lowers plasma insulin levels in insulin-resistant obese subjects and patients with type 2 diabetes, would also lower circulating PAI-1 antigen concentrations and activity." | 3.70 | Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. ( Kruszynska, YT; Olefsky, JM; Sobel, BE; Yu, JG, 2000) |
| "Troglitazone is a new orally active hypoglycemic agent that has been shown to ameliorate insulin resistance and hyperinsulinemia in both diabetic animal models and non-insulin-dependent diabetes mellitus (NIDDM) subjects." | 3.69 | Metabolic effects of troglitazone on fat-induced insulin resistance in the rat. ( Gao, KM; Khoursheed, M; Lee, MK; Miles, PD; Moossa, AR; Olefsky, JM, 1995) |
| "Troglitazone, a newly developed oral antidiabetic agent, improves hyperglycemia, and has been reported to improve insulin resistance and to decrease hepatic glucose production in diabetic animals." | 3.69 | Effect of troglitazone, a new oral antidiabetic agent, on fructose-induced insulin resistance. ( Higa, S; Ishikawa, K; Mimura, G; Murakami, K; Takasu, N; Yagi, N, 1995) |
| " Troglitazone is an insulin-sensitizing thiazolidinedione, which improves hepatic and skeletal muscle insulin resistance in NIDDM and obesity." | 3.69 | Effect of troglitazone on leptin production. Studies in vitro and in human subjects. ( Caro, JF; Considine, RV; Nolan, JJ; Nyce, MR; Olefsky, JM, 1996) |
| "Insulin resistance is associated with a decreased vasodilator response to insulin." | 2.69 | Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone. ( Lutterman, JA; Ong, MK; Smits, P; Tack, CJ, 1998) |
| " However, a significant proportion of women with PCOS fail to ovulate with the use of standard dosage of CC and are called CC-resistant PCOS." | 2.42 | Minireview: Up-date management of non responder to clomiphene citrate in polycystic ovary syndrome. ( Abd el-Aal, G; Abdel-Kareem, O; Amin, M; Maruo, T; Moriyama, T; Takekida, S, 2003) |
| "Insulin resistance syndrome is the theory that glucose intolerance, hyperinsulinemia, increased very low density lipoprotein triglyceride level, decreased high density lipoprotein cholesterol level, and hypertension are proposed consequences of insulin resistance." | 2.41 | [Insulin sensitizer and hypertension]. ( Shimamoto, K, 2000) |
| "Moreover, hypertension was reported to be a possible cause of insulin resistance." | 2.40 | [Insulin, as a regulating factor of blood pressure]. ( Hamada, Y; Ikegami, H; Ogihara, T, 1997) |
| "In conclusion, improvement of hyperinsulinemia can decrease NHE activity and blood pressure in fructose-fed BHR." | 1.32 | Troglitazone reduces activity of the Na+/H+ exchanger in fructose-fed borderline hypertensive rats. ( Fujioka, Y; Iwasaki, T; Masai, M; Morimoto, S; Ohyanagi, M; Okumura, T; Tsuboi, S; Tsujino, T, 2003) |
| "Troglitazone treatment significantly increased pancreatic wet weight and protein, DNA, and enzyme contents compared with those in the control rats." | 1.31 | Troglitazone stimulates pancreatic growth in congenitally CCK-A receptor-deficient OLETF rats. ( Akiyama, T; Fukumitsu, KI; Jia, DM; Otsuki, M; Tabaru, A, 2001) |
| "Troglitazone treatment completely prevented the TNF-alpha-induced decline in submaximal GDR (133 +/- 16 vs." | 1.30 | TNF-alpha-induced insulin resistance in vivo and its prevention by troglitazone. ( Cohen, A; Higo, K; Miles, PD; Olefsky, JM; Rafaat, K; Romeo, OM, 1997) |
| "Since WHHL rabbits show hyperinsulinemia and insulin resistance, we administered troglitazone (100 mg/kg), an insulin action enhancer, pravastatin sodium (50 mg/kg), an HMG CoA reductase inhibitor, and a combination of both drugs to 2-month-old WHHL rabbits for 32 weeks." | 1.30 | Combination treatment with troglitazone, an insulin action enhancer, and pravastatin, an inhibitor of HMG-CoA reductase, shows a synergistic effect on atherosclerosis of WHHL rabbits. ( Horikoshi, H; Ito, T; Shiomi, M; Tsujita, Y; Tsukada, T, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 22 (56.41) | 18.2507 |
| 2000's | 16 (41.03) | 29.6817 |
| 2010's | 1 (2.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Martins, FO | 1 |
| Delgado, TC | 1 |
| Viegas, J | 1 |
| Gaspar, JM | 1 |
| Scott, DK | 1 |
| O'Doherty, RM | 1 |
| Macedo, MP | 1 |
| Jones, JG | 1 |
| Kono, S | 1 |
| Fujioka, Y | 1 |
| Masai, M | 1 |
| Tsuboi, S | 1 |
| Okumura, T | 1 |
| Morimoto, S | 1 |
| Tsujino, T | 1 |
| Ohyanagi, M | 1 |
| Iwasaki, T | 1 |
| Sekino, N | 1 |
| Kashiwabara, A | 1 |
| Inoue, T | 1 |
| Kawasaki, T | 1 |
| Ogata, N | 1 |
| Sawashige, K | 1 |
| Yamanouchi, T | 1 |
| Azziz, R | 1 |
| Ehrmann, DA | 2 |
| Legro, RS | 1 |
| Fereshetian, AG | 1 |
| O'Keefe, M | 1 |
| Ghazzi, MN | 1 |
| Amin, M | 1 |
| Abdel-Kareem, O | 1 |
| Takekida, S | 1 |
| Moriyama, T | 1 |
| Abd el-Aal, G | 1 |
| Maruo, T | 1 |
| Levin, K | 1 |
| Hother-Nielsen, O | 1 |
| Henriksen, JE | 1 |
| Beck-Nielsen, H | 1 |
| Khoursheed, M | 1 |
| Miles, PD | 2 |
| Gao, KM | 1 |
| Lee, MK | 1 |
| Moossa, AR | 1 |
| Olefsky, JM | 4 |
| Reusch, JE | 1 |
| Nolan, JJ | 2 |
| Ludvik, B | 1 |
| Beerdsen, P | 1 |
| Joyce, M | 1 |
| Olefsky, J | 1 |
| Yagi, N | 1 |
| Takasu, N | 1 |
| Higa, S | 1 |
| Ishikawa, K | 1 |
| Murakami, K | 1 |
| Mimura, G | 1 |
| Nyce, MR | 1 |
| Considine, RV | 1 |
| Caro, JF | 1 |
| Henry, RR | 1 |
| Petrie, J | 1 |
| Small, M | 1 |
| Connell, J | 1 |
| Nestler, JE | 1 |
| Mantzoros, CS | 1 |
| Dunaif, A | 1 |
| Flier, JS | 1 |
| Hamada, Y | 1 |
| Ikegami, H | 1 |
| Ogihara, T | 1 |
| Romeo, OM | 1 |
| Higo, K | 1 |
| Cohen, A | 1 |
| Rafaat, K | 1 |
| Okuno, A | 1 |
| Tamemoto, H | 1 |
| Tobe, K | 1 |
| Ueki, K | 1 |
| Mori, Y | 1 |
| Iwamoto, K | 1 |
| Umesono, K | 1 |
| Akanuma, Y | 1 |
| Fujiwara, T | 2 |
| Horikoshi, H | 3 |
| Yazaki, Y | 1 |
| Kadowaki, T | 2 |
| van Montfrans, JM | 1 |
| van Hooff, MH | 1 |
| Hompes, PG | 1 |
| Lambalk, CB | 1 |
| Uchiyama, K | 2 |
| Nakai, I | 2 |
| Mitsuo, M | 2 |
| Shimizu, Y | 1 |
| Oka, T | 2 |
| Takata, Y | 1 |
| Kobayashi, M | 1 |
| Tack, CJ | 1 |
| Ong, MK | 1 |
| Lutterman, JA | 1 |
| Smits, P | 1 |
| Sattar, N | 1 |
| Hopkinson, ZE | 1 |
| Greer, IA | 1 |
| Shibata, T | 1 |
| Matsui, K | 1 |
| Nagao, K | 1 |
| Shinkai, H | 1 |
| Yonemori, F | 1 |
| Wakitani, K | 1 |
| Shiomi, M | 1 |
| Ito, T | 1 |
| Tsukada, T | 1 |
| Tsujita, Y | 1 |
| Mizuta, N | 1 |
| Okamoto, M | 1 |
| Nakajima, H | 1 |
| Yoshimura, N | 1 |
| Omori, Y | 1 |
| Zimmet, P | 1 |
| Collier, G | 1 |
| Kusano, S | 1 |
| Abe, H | 1 |
| Shimamoto, K | 1 |
| Yamada, K | 1 |
| Kuzuya, H | 1 |
| Nakano, T | 1 |
| Kruszynska, YT | 1 |
| Yu, JG | 1 |
| Sobel, BE | 1 |
| Kakuma, T | 1 |
| Lee, Y | 1 |
| Higa, M | 1 |
| Wang, Zw | 1 |
| Pan, W | 1 |
| Shimomura, I | 1 |
| Unger, RH | 1 |
| McCarthy, KJ | 1 |
| Routh, RE | 1 |
| Shaw, W | 1 |
| Walsh, K | 1 |
| Welbourne, TC | 1 |
| Johnson, JH | 1 |
| Jia, DM | 1 |
| Fukumitsu, KI | 1 |
| Tabaru, A | 1 |
| Akiyama, T | 1 |
| Otsuki, M | 1 |
| Harano, Y | 1 |
| Chvojková, S | 1 |
| Kazdová, L | 1 |
| Divisová, J | 1 |
| Wada, M | 1 |
| Fukuda, K | 1 |
| Fukami, M | 1 |
| Yoshioka, S | 1 |
| Yoshioka, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Rosiglitazone And Fenofibrate Additive Effects on Lipids (RAFAEL)[NCT00819910] | Phase 4 | 41 participants (Actual) | Interventional | 2008-09-30 | Terminated (stopped due to Slow recruitment and increase in deployment overseas limiting follow up) | ||
| Study of PPAR Gamma Agonist-Rosiglitazone in Normotensive Type 2 Diabetics With Ambulatory Blood Pressure Monitoring[NCT00290394] | Phase 4 | 25 participants | Interventional | 2004-03-31 | Completed | ||
| Rosiglitazone Intervention Study in Patients With Type 1.5 Diabetes[NCT00194896] | 64 participants (Actual) | Interventional | 2000-02-29 | Completed | |||
| [NCT01626443] | Phase 4 | 46 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| The Effect of Acupuncture on Insulin Sensitivity of Women With Polycystic Ovary Syndrome and Insulin Resistance: a Randomized Controlled Trial[NCT02491333] | Phase 3 | 342 participants (Actual) | Interventional | 2015-08-31 | Completed | ||
| Effect of Metformin on Insulin Sensitivity and Pan-Arterial Vascular Function in Adults With Metabolic Syndrome[NCT02633488] | 19 participants (Actual) | Interventional | 2014-06-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The reported percent change is the difference between TG levels obtained on initial visit (day 0) and TG levels obtained at final visit (week 12) as per protocol (NCT00819910)
Timeframe: 12 weeks from initial visit (day 0) to final visit (12 weeks)
| Intervention | % change (Mean) |
|---|---|
| Rosiglitazone + Placebo | 7.4 |
| Fenofibrate + Placebo | -2.2 |
| Rosiglitazone +Fenofibrate | 20 |
| Placebo Therapy Daily | 7.6 |
The reported percent change is the difference between HDL levels obtained on initial visit (day 0) and HDL levels obtained at final visit (week 12) as per protocol (NCT00819910)
Timeframe: 12 weeks from initial visit (day 0) to final visit (12 weeks)
| Intervention | % change (Mean) |
|---|---|
| Rosiglitazone and Placebo | 1.9 |
| Fenofibrate + Placebo | 14.5 |
| Rosiglitazone +Fenofibrate | 5.8 |
| Placebo Therapy Daily | 1.7 |
The reported percent change is the difference between LDL levels obtained on initial visit (day 0) and LDL levels obtained at final visit (week 12) as per protocol (NCT00819910)
Timeframe: 12 weeks from initial visit (day 0) to final visit (12 weeks)
| Intervention | % change (Mean) |
|---|---|
| Rosiglitazone + Placebo | -0.5 |
| Fenofibrate + Placebo | 2.6 |
| Rosiglitazone + Fenofibrate | 37.3 |
| Placebo Therapy Daily | 13.7 |
The mean Levels of AST and ALT measured at initial visit (Day 0) and final visit (Week 12) annotated as AST 1, AST 12, and ALT 1 and ALT 12, respectively. (NCT00819910)
Timeframe: 12 weeks from initial visit (day 0) to final visit (12 weeks)
| Intervention | mg/dl (Mean) | |||
|---|---|---|---|---|
| AST 1 (aspartate aminotransferase [10-35 U/L]) | AST 12 (aspartate aminotransferase [15-37 U/L]) | ALT 1 (alanine aminotransferase [6-60 U/L]) | ALT 12 (alanine aminotransferase [6-60 U/L]) | |
| Fenofibrate + Placebo | 25.25 | 26.50 | 25.88 | 26.38 |
| Placebo Therapy Daily | 19.88 | 17.88 | 20.88 | 14.88 |
| Rosiglitazone + Placebo | 24.00 | 30.29 | 28.14 | 27.43 |
| Rosiglitazone +Fenofibrate | 24.30 | 19.70 | 24.10 | 21.10 |
Post-treatment median change in Apo AI, Apo AII and Apo CIII levels reported in mg/dL with Interquartile ranges provided (NCT00819910)
Timeframe: 12 weeks from initial visit (day 0) to final visit (12 weeks)
| Intervention | % Change (Median) | ||
|---|---|---|---|
| Apo AI | Apo AII | Apo CIII | |
| Fenofibrate + Placebo | 13 | 3.4 | -4.35 |
| Placebo Therapy Daily | 5 | -3.5 | -2.3 |
| Rosiglitazone + Placebo | -1.00 | 10.25 | 0.30 |
| Rosiglitazone +Fenofibrate | 1 | 7.2 | -5.3 |
Number of participants positive for T cell reactivity to islet proteins at 36 months. (NCT00194896)
Timeframe: 36 months
| Intervention | participants (Number) |
|---|---|
| Rosiglitazone Autoantibody Positive | 1 |
| Rosiglitazone Autoantibody Negative | 2 |
| Glyburide Autoantibody Positive | 2 |
| Glyburide Autoantibody Negative | 3 |
Changes in beta cell function assessed by fasting and stimulated C-peptide measured at 36 months. (NCT00194896)
Timeframe: 36 months
| Intervention | ng per ml (Mean) | |
|---|---|---|
| Fasting C-peptide | Glucagon Stimulated C-peptide | |
| Glyburide Autoantibody Negative | 0.3 | 0.3 |
| Glyburide Autoantibody Positive | 0.1 | 3.1 |
| Rosiglitazone Autoantibody Negative | -1.4 | -2.8 |
| Rosiglitazone Autoantibody Positive | -0.4 | -0.6 |
brachial artery ultrasonography % flow-mediated dilatation (FMD) for assessing endothelial function before and after an insulin clamp to assess insulin's effect on the vasculature (NCT02633488)
Timeframe: before and after 12 weeks on placebo or metformin
| Intervention | percentage of artery dilation (Mean) |
|---|---|
| Pre and Post Placebo 12 Weeks | 6.1 |
| Pre and Post Metformin 12 Weeks | 6.2 |
12 reviews available for troglitazone and Hyperinsulinism
| Article | Year |
|---|---|
[Insulin resistance in myotonic dystrophy].
Topics: Chromans; Humans; Hyperinsulinism; Insulin Resistance; Insulin-Like Growth Factor I; Myotonic Dystro | 2002 |
Minireview: Up-date management of non responder to clomiphene citrate in polycystic ovary syndrome.
Topics: Anovulation; Chromans; Clomiphene; Drug Resistance; Drug Therapy, Combination; Female; Gynecologic S | 2003 |
Effects of troglitazone on insulin sensitivity.
Topics: Animals; Blood Glucose; Blood Pressure; Chromans; Diabetes Mellitus, Type 2; Glucose Intolerance; Gl | 1996 |
Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications.
Topics: Adrenal Glands; Androgens; Anovulation; Chromans; Diazoxide; Female; Humans; Hyperinsulinism; Hypogl | 1997 |
Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications.
Topics: Adrenal Glands; Androgens; Anovulation; Chromans; Diazoxide; Female; Humans; Hyperinsulinism; Hypogl | 1997 |
Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications.
Topics: Adrenal Glands; Androgens; Anovulation; Chromans; Diazoxide; Female; Humans; Hyperinsulinism; Hypogl | 1997 |
Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications.
Topics: Adrenal Glands; Androgens; Anovulation; Chromans; Diazoxide; Female; Humans; Hyperinsulinism; Hypogl | 1997 |
[Insulin, as a regulating factor of blood pressure].
Topics: Animals; Cell Division; Chromans; Humans; Hyperinsulinism; Hypertension; Hypoglycemic Agents; Insuli | 1997 |
Treatment of hyperinsulinaemia in polycystic ovary syndrome?
Topics: Chromans; Diazoxide; Female; Humans; Hyperinsulinism; Hypoglycemic Agents; Metformin; Polycystic Ova | 1998 |
Attenuation of hyperinsulinemia in polycystic ovary syndrome: what are the options?
Topics: Chromans; Female; Humans; Hyperinsulinism; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome | 1998 |
Clinical efficacy of metformin against insulin resistance parameters: sinking the iceberg.
Topics: Animals; Blood Glucose; Cardiovascular Diseases; Chromans; Diabetes Mellitus, Type 2; Diabetic Angio | 1999 |
[Insulin sensitizer and hypertension].
Topics: Animals; Cholesterol, HDL; Cholesterol, LDL; Chromans; Humans; Hyperinsulinism; Hypertension; Hypogl | 2000 |
[Cardiovascular effects of the thiazolidinedione troglitazone].
Topics: Animals; Arteriosclerosis; Cardiovascular Diseases; Cardiovascular System; Chromans; Diabetes Mellit | 2000 |
[Hypoglycemic agents to improve insulin resistance].
Topics: Adipocytes; Animals; Cell Differentiation; Chromans; Diabetes Mellitus, Type 2; Disease Models, Anim | 2000 |
[Lipodystrophia].
Topics: Animals; Cardiomyopathy, Hypertrophic; Chromans; Diabetes Mellitus; Diagnosis, Differential; Fatty L | 2001 |
7 trials available for troglitazone and Hyperinsulinism
| Article | Year |
|---|---|
Usefulness of troglitazone administration to obese hyperglycaemic patients with near-normoglycaemia.
Topics: Adult; Aged; Blood Glucose; Chromans; Deoxyglucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fe | 2003 |
Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome.
Topics: Adrenal Glands; Adult; Blood Glucose; Chromans; Dehydroepiandrosterone Sulfate; Dose-Response Relati | 2003 |
Effects of troglitazone in young first-degree relatives of patients with type 2 diabetes.
Topics: Blood Glucose; Chromans; Denmark; Diabetes Mellitus, Type 2; Family; Glucose Clamp Technique; Glucos | 2004 |
Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.
Topics: Adult; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Tole | 1994 |
Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.
Topics: Adult; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Tole | 1994 |
Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.
Topics: Adult; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Tole | 1994 |
Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.
Topics: Adult; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Tole | 1994 |
Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.
Topics: Adult; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Tole | 1994 |
Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.
Topics: Adult; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Tole | 1994 |
Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.
Topics: Adult; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Tole | 1994 |
Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.
Topics: Adult; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Tole | 1994 |
Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.
Topics: Adult; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Tole | 1994 |
Leptin concentrations in the polycystic ovary syndrome.
Topics: Adult; Body Mass Index; Chromans; Double-Blind Method; Female; Humans; Hyperinsulinism; Hypoglycemic | 1997 |
Treatment of hyperinsulinaemia in polycystic ovary syndrome?
Topics: Chromans; Diazoxide; Female; Humans; Hyperinsulinism; Hypoglycemic Agents; Metformin; Polycystic Ova | 1998 |
Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone.
Topics: Acetylcholine; Adult; Analysis of Variance; Biomarkers; Blood Glucose; Cardiovascular System; Case-C | 1998 |
21 other studies available for troglitazone and Hyperinsulinism
| Article | Year |
|---|---|
Mechanisms by which the thiazolidinedione troglitazone protects against sucrose-induced hepatic fat accumulation and hyperinsulinaemia.
Topics: Animals; Chromans; Fatty Liver; Hyperinsulinism; Hypoglycemic Agents; Male; Protective Agents; Rats; | 2016 |
Troglitazone reduces activity of the Na+/H+ exchanger in fructose-fed borderline hypertensive rats.
Topics: Animals; Bezafibrate; Blood Glucose; Blood Platelets; Blood Pressure; Calcium; Chromans; Diet; Eicos | 2003 |
Metabolic effects of troglitazone on fat-induced insulin resistance in the rat.
Topics: Animals; Blood Pressure; Body Weight; Chromans; Dietary Fats; Eating; Glucose; Glucose Clamp Techniq | 1995 |
New directions in treating insulin resistance.
Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistanc | 1995 |
Effect of troglitazone, a new oral antidiabetic agent, on fructose-induced insulin resistance.
Topics: Aging; Animals; Blood Glucose; Body Weight; Chromans; Fructose; Hyperinsulinism; Hypoglycemic Agents | 1995 |
Effect of troglitazone on leptin production. Studies in vitro and in human subjects.
Topics: Adipocytes; Adult; Animals; Blood Glucose; Cells, Cultured; Chromans; Fasting; Female; Glucose; Huma | 1996 |
"Glitazones", a prospect for non-insulin-dependent diabetes.
Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistanc | 1997 |
TNF-alpha-induced insulin resistance in vivo and its prevention by troglitazone.
Topics: Adenosine Triphosphate; Animals; Blood Glucose; Chromans; Fatty Acids, Nonesterified; Glucose Clamp | 1997 |
Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats.
Topics: Adipocytes; Adipose Tissue; Animals; Apoptosis; Blood Glucose; Blotting, Northern; Body Weight; Chro | 1998 |
Surgical and chemical approaches to regulate hyperinsulinemia after pancreas transplantation in rats.
Topics: Animals; Chromans; Diabetes Mellitus, Experimental; Drainage; Hyperinsulinism; Hypoglycemic Agents; | 1998 |
Insulin-sensitising agents in polycystic-ovary syndrome.
Topics: Chromans; Controlled Clinical Trials as Topic; Female; Humans; Hyperinsulinism; Hypoglycemic Agents; | 1998 |
Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative.
Topics: 3T3 Cells; Administration, Oral; Animals; Blood Glucose; Cell Differentiation; Chromans; Diabetes Me | 1999 |
Combination treatment with troglitazone, an insulin action enhancer, and pravastatin, an inhibitor of HMG-CoA reductase, shows a synergistic effect on atherosclerosis of WHHL rabbits.
Topics: Animals; Aorta, Thoracic; Arteriosclerosis; Blood Glucose; Cholesterol, LDL; Chromans; Coronary Vess | 1999 |
Elimination of hyperinsulinemia after pancreas transplantation in rats.
Topics: Animals; Chromans; Hyperinsulinism; Hypoglycemic Agents; Male; Pancreas Transplantation; Portal Syst | 1999 |
Antidiabetic activity of white skinned sweet potato (Ipomoea batatas L.) in obese Zucker fatty rats.
Topics: Animals; Blood Glucose; Chromans; Fatty Acids, Nonesterified; Glucose Tolerance Test; Hyperinsulinis | 2000 |
Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.
Topics: Adult; Arteriosclerosis; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Female; Fibrinolysis; G | 2000 |
Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets.
Topics: Adenoviridae; Animals; CCAAT-Enhancer-Binding Proteins; Chromans; DNA-Binding Proteins; Genetic Vect | 2000 |
Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion.
Topics: Animals; Basement Membrane; Body Weight; Chondroitin Sulfate Proteoglycans; Chromans; Diabetes Melli | 2000 |
Troglitazone stimulates pancreatic growth in congenitally CCK-A receptor-deficient OLETF rats.
Topics: Aging; Amylases; Animals; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Fibrosis; Homeostasis; | 2001 |
A comparison of the effects of troglitazone and vitamin E on the fatty acid composition of serum phospholipids in an experimental model of insulin resistance.
Topics: Animals; Antioxidants; Blood Glucose; Blood Pressure; Chromans; Disease Models, Animal; Fatty Acids; | 2001 |
Characterization of CS-045, a new oral antidiabetic agent, II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/KsJ-db/db mice.
Topics: Administration, Oral; Animals; Blood Glucose; Chromans; Diabetes Mellitus; Glucagon; Hyperglycemia; | 1991 |